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CORRESPONDENCE
Dietary Guidelines Head North
Minnesota Medical Association is covering issues 
related to food and nutrition in the September/October 
issue of Minnesota Medicine. We noticed the article in 
your March/April issue by James J. DiNicolantonio, Zoe 
Harcombe and James O’Keefe, “Problems with the 2015 
Dietary Guidelines for Americans: An Alternative.”
We thought it was very well done and offered very 
useful information. We would like to reprint it for our 






I read with interest the review article from Missouri 
Medicine (May/June 2016), entitled “Over-Prescribed 
Medications, Under-Appreciated Risks: A Review of the 
Cognitive Effects of Anticholinergic Medications in Older 
Adults” by Daniel M. I. Britt and Dr. Gregory Day from 
Washington University in St. Louis.
This article discusses an important topic, the cognitive 
effects of anticholinergic medications in older adults. The 
authors point to a number of previous studies showing 
an association between cognitive impairment and use 
of anticholinergic medications and summarize with the 
consensus finding that older adults taking anticholinergic 
medications are at higher risk for cognitive impairment and 
dementia. 
Our recent report in the Journal of the American Medical 
Association - Neurology entitled “Association between 
Anticholinergic Medication Use and Cognition, Brain 
Metabolism, and Brain Atrophy in Cognitively Normal 
Older Adults” supports Mr. Britt and Dr. Day’s conclusion 
of an association of anticholinergic medication use in older 
adults with both decreased cognition and increased risk for 
dementia in older adults. 
Further, our study was the first to provide in vivo 
measures of structural and functional brain changes in 
that may underlie the observed association. Our study 
examined older adults (mean age = 73.3 years) who 
were cognitively normal at the time of baseline exam 
from a consortium study on neuroimaging measures in 
Alzheimer’s disease (AD) called the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI), as well as a secondary 
cohort of cognitively normal older adults from the 
Indiana Memory and Aging Study (IMAS; mean age = 
70.3 years). Both cohorts underwent cognitive testing of 
memory and executive function and structural magnetic 
resonance imaging (MRI) to measures brain volume. The 
ADNI participants also underwent baseline functional 
neuroimaging with positron emission tomography (PET) 
using [18F]FDG to examine brain glucose metabolism and 
longitudinal clinical follow-up (mean follow-up period 
= 32.1 months). We then compared cognition, brain 
glucose metabolism and volume, and risk of conversion 
to a diagnosis of mild cognitive impairment (MCI) or AD 
over the follow-up period between older adults taking 
one or more anticholinergic medications (AC+) to those 
not taking anticholinergic medications (AC-).  Similar to 
previous reports, we found significantly lower memory and 
executive function in AC+ older adults relative to AC- 
older adults, as well as a 2.5x increased risk of conversion 
to MCI and/or AD (which increases to a more than 7x 
increased risk in those that are also amyloid positive) in 
AC+ older adults relative to AC- older adults. 
Further, we found reduced brain glucose metabolism 
and greater atrophy across the whole brain, as well as 
more specifically in the temporal lobe, a region important 
for memory and other types of cognition. Overall, we 
concluded that use of anticholinergic medications should 
be discouraged in older adults if alternatives are available, 
although additional longitudinal prospective studies are 
needed to fully understand the role of anticholinergic 
medications on cognitive impairment and associated brain 
pathology. 
The article published by Mr. Britt and Dr. Day raises 
important and timely issues about the use of anticholinergic 
medications in older populations, and I feel is an excellent 
resource for researchers and clinicians who are concerned 
about or interested in the use of anticholinergic medications 
in these populations.
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